Report of Foreign Issuer (6-k)
October 16 2017 - 8:34AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
October 16, 2017
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 16 October 2017
–
On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014
of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part
of the overall share repurchase programme of up to DKK 16 billion to be executed during a 12-month period beginning 2 February
2017.
Under the programme initiated 9 August 2017, Novo Nordisk will repurchase
B shares for an amount up to DKK 3.9 billion in the period from 9 August 2017 to 30 October 2017.
Since the announcement as of 9 October 2017, the
following transactions have been made under the programme:
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
Accumulated, last announcement
|
9,634,590
|
|
2,861,430,269
|
9 October 2017
|
210,000
|
310.98
|
65,305,498
|
10 October 2017
|
210,000
|
306.89
|
64,447,103
|
11 October 2017
|
220,000
|
308.20
|
67,804,631
|
12 October 2017
|
215,000
|
309.20
|
66,478,275
|
13 October 2017
|
215,000
|
302.76
|
65,093,542
|
|
|
|
|
Accumulated under the programme
|
10,704,590
|
|
3,190,559,318
|
The details for each transaction made
under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 43,756,113
B shares of DKK 0.20, corresponding to 1.8% of the share capital, as treasury shares. The total amount of A and B shares in the
company is 2,500,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 16 billion during a 12-month period beginning
2 February 2017. As of 13 October 2017, Novo Nordisk has repurchased a total of 42,652,561 B shares equal to a transaction value
of DKK 11,490,531,310.
Novo Nordisk is
a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us
experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders
and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products
in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
|
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Hanna Ögren
|
+45 3079 8519
|
haoe@novonordisk.com
|
Anders Mikkelsen
|
+45 3079 4461
|
armk@novonordisk.com
|
Christina Kjær
|
+45 3079 3009
|
cnje@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 78 / 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: October 16, 2017
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Sep 2023 to Sep 2024